{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:sotatercept",
  "owner": "cardio",
  "kind": "drug",
  "slug": "sotatercept",
  "name": "Sotatercept",
  "aliases": [
    "Winrevair",
    "Sotatercept-csrk"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Sotatercept, sold as Winrevair, is an activin signaling inhibitor. The US label lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization functional class, and to reduce the risk of clinical worsening events. The label describes it as a recombinant activin receptor type IIA-Fc fusion protein. It is filed under the class page for activin signaling inhibitors, of which it is the only member.",
  "summary_technical": "RxNorm ingredient 2678930. The openFDA label record carries no UNII and no substance name, and the Drugs@FDA ingredient string is SOTATERCEPT-CSRK, kept as an alias. MeSH has no descriptor for sotatercept (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Activin Signaling Inhibitor (and the mechanism class Activin Signaling Inhibitors), with sotatercept as the only member, so the record is filed under the class page for activin signaling inhibitors on that evidence; the Winrevair label also calls it an activin signaling inhibitor. The label read is the Merck Sharp & Dohme LLC label for Winrevair, application BLA761363, effective 2026-09-21 in openFDA. This page records the label indication, the mechanism sentence and the class name only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "2678930",
      "normalized_value": "2678930",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says sotatercept-csrk, a recombinant activin receptor type IIA-Fc fusion protein, is an activin signaling inhibitor."
  },
  "content_digest": "a261e46371eb17d59249d1e9a48b340439b8a3bf26aea1327c01041ab21fa018",
  "review": {
    "content_digest": "a261e46371eb17d59249d1e9a48b340439b8a3bf26aea1327c01041ab21fa018",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-winrevair-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:sotatercept",
      "category": "descriptive",
      "statement": "The US label of Winrevair (sotatercept-csrk, Merck Sharp & Dohme LLC, application BLA761363; the version dated 2026-09-21 in openFDA) describes the medicine as an activin signaling inhibitor. It lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events.",
      "context": {
        "id": "cardio:ctx-fda-winrevair-label-us",
        "label": "Adults with pulmonary arterial hypertension, as described in the US label of Winrevair",
        "recipient": "adult",
        "population": "Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, BLA761363.",
          "snapshot": {
            "id": "cardio:openfda-label-winrevair-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:46Z",
            "content_hash": "2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536",
            "source_effective_date": "2026-09-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-winrevair",
            "source_type": "regulator",
            "title": "openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-21693ee2-cd23-4137-ac67-066bb3a4a9b7.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260921.",
          "snapshot": {
            "id": "cardio:openfda-label-winrevair-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:46Z",
            "content_hash": "2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536",
            "source_effective_date": "2026-09-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-winrevair",
            "source_type": "regulator",
            "title": "openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-21693ee2-cd23-4137-ac67-066bb3a4a9b7.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-SOT-LB-03, Q-K30-SOT-LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-winrevair-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:46Z",
            "content_hash": "2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536",
            "source_effective_date": "2026-09-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-winrevair",
            "source_type": "regulator",
            "title": "openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-21693ee2-cd23-4137-ac67-066bb3a4a9b7.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "8bdd079d3ba075e27cf0bca2162299d22cbfa5451715fd8844b843b4541ec7df",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-winrevair-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Sotatercept is an activin signaling inhibitor (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:activin-signaling-inhibitors",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2678930-2026-11-19",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[0].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension in adults, to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-winrevair-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/sotatercept/",
  "context_path": "api/v1/context/cardio--sotatercept.md"
}
